CClinicalTrials.gg
Active, not recruitingNCT07275502Updated Dec 10, 2025

Prospective Development and Validation of an Objective Classification for Difficult Facemask Ventilation: the MASCAN Score

An observational study in Airway Management, Mask Ventilation and Noninvasive Ventilation, sponsored by Universitätsklinikum Hamburg-Eppendorf. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
423
Ages
18 Years and older
Sex
All
01

Study summary

Difficult facemask ventilation remains poorly classified. Existing definitions rely on expert opinion and subjective rating of surrogates. This lack of standardization has led to highly variable reported incidences and inconsistencies in clinical practice and research.

This secondary analysis of the prospective observational MASCAN study aims to develop and validate a data-driven objective classification system for difficult facemask ventilation and to determine its diagnostic performance and calibration. Facemask ventilation was facilitated after anaesthesia induction in all patients. An independent observer systematically assessed potential indicators for difficult facemask ventilation that serve as candidate predictor variables for the fitting of a diagnostic multivariable logistic regression model and simplified score to classify difficult facemask ventilation. Cross-validated LASSO regression will be used for variable selection. The area under the receiver operating characteristic curve (AUROC) and calibration curves will be used to quantify the diagnostic performance and calibration, and optimal decision thresholds will be defined.

02

Conditions studied

  • Airway Management
  • Mask Ventilation
  • Noninvasive Ventilation

Keywords

  • Difficult facemask ventilation
03

In context

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 403 studies on the registry; 83 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive sampling: Adult patients that undergo ENT or OMS surgery in a tertiary care hospital who require facemask ventilation and tracheal intubation after induction of anesthesia.

Inclusion criteria

  • Patients scheduling for ENT or OMS surgery in general anaesthesia, who require facemask ventilation and tracheal intubation after induction of anesthesia
  • Patients aged at least 18 years
  • Ability to understand the patient information and to personally sign and date the informed consent to participate in the study
  • The patient is co-operative and available for the entire study
  • Provided informed consent/patient representative

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding woman
  • Rapid sequence induction or other contraindications for facemask ventilation
  • Planned awake tracheal intubation
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
423 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Difficult facemask ventilation

    Alert documented in patients' health records by the airway operator following facemask ventilation (y/n)

    Time frame: 1 hour

Secondary outcomes

  1. Impossible facemask ventilation

    Observed impossible facemask ventilation after induction of anaesthesia (y/n)

    Time frame: 1 hour

  2. Airway-related adverse events

    Laryngospasm, bronchospasm, larynx trauma, airway trauma, soft tissue trauma, oral bleeding, edema, dental damage, corticosteroid application, accidental esophageal intubation, aspiration, hypotension or hypoxia

    Time frame: 1 hour

07

Study locations

1 site
  • Department of Anesthesiology, Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07275502
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Nov 7, 2022
Primary completion
May 15, 2023
Completion
Nov 30, 2025 (estimated)
Last update
Dec 10, 2025

Study contacts

Martin Petzoldt, MD
principal investigator · University Medical Centre Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion